Wall Street brokers expect Immuneering Co. (NASDAQ:IMRX – Get Rating) to post earnings per share of ($0.51) for the current quarter, according to Zacks Investment Research. Four analysts released estimates of Immuneering’s earnings, with estimates ranging from ($0.54) to ($0.46). Immuneering reported earnings per share of ($1.61) in the same quarter last year, indicating a positive growth rate of 68.3% year over year. The company is expected to release its next quarterly earnings report on Monday, January 1.
According to Zacks, analysts expect Immuneering to report full year earnings of ($2.10) per share for the current fiscal year, with EPS estimates ranging from ($2.25) to ($1. $.83). For the next fiscal year, analysts expect the company to post earnings of ($2.43) per share, with EPS estimates ranging from ($2.83) to ($2.02). Zacks earnings per share averages are an average average based on a survey of analysts who provide coverage for Immuneering.
Immuneering (NASDAQ:IMRX – Get Rating) last released quarterly earnings data on Thursday, March 10. The company reported ($0.42) earnings per share for the quarter, missing analyst consensus estimates of ($0.39) by ($0.03). Immuneering had a negative return on equity of 38.00% and a negative net margin of 2,651.85%. The company posted revenue of $0.19 million in the quarter, compared to $0.60 million expected by analysts.
Several research companies have published reports on IMRX. Oppenheimer began covering Immuneering in a research note on Thursday, March 31. They issued an “outperform” rating and a target price of $25.00 on the stock. Zacks Investment Research downgraded Immuneering from a “buy” rating to a “hold” rating in a Friday, May 13 report. Two analysts rated the stock with a hold rating and five gave the company a buy rating. According to MarketBeat.com, the stock has an average buy rating and consensus price target of $29.13.
In other Immuneering news, Director Ann E. Berman acquired 6,000 shares of the company in a transaction dated Tuesday, March 15. The shares were acquired at an average cost of $6.40 per share, for a total transaction of $38,400.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this link. Additionally, director Laurie Keating purchased 7,000 shares of the company in a transaction dated Monday, May 16. The shares were acquired at an average price of $5.00 per share, for a total transaction of $35,000.00. As a result of the transaction, the administrator now directly owns 14,000 shares of the company, valued at $70,000. Disclosure of this purchase can be found here. Insiders acquired a total of 21,451 shares of the company worth $123,501 over the past ninety days.
Institutional investors have recently changed their positions in the company. UBS Group AG bought a new position in shares of Immuneering during the third quarter for a value of $30,000. Citigroup Inc. purchased a new stake in Immuneering during the third quarter worth approximately $33,000. California State Teachers Retirement System increased its stake in Immuneering by 81.8% during the first quarter. California State Teachers Retirement System now owns 8,124 shares of the company worth $53,000 after purchasing 3,656 additional shares during the period. American International Group Inc. increased its equity stake in Immuneering by 111.1% in the first quarter. American International Group Inc. now owns 9,432 shares of the company valued at $61,000 after purchasing an additional 4,964 shares during the period. Finally, Metropolitan Life Insurance Co NY purchased a new stake in Immuneering during Q3 for approximately $75,000. 47.41% of the shares are currently held by institutional investors and hedge funds.
NASDAQ IMRX opened at $4.48 on Wednesday. The company has a market capitalization of $118.23 million and a PE ratio of -1.50. Immuneering has a 52 week minimum of $3.74 and a 52 week maximum of $33.99. The company’s 50-day moving average price is $5.78 and its 200-day moving average price is $11.36.
About Immunization (Get a rating)
Immuneering Corporation, a biopharmaceutical company, is focused on product candidates in oncology and neuroscience. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat cancer patients, including pancreatic cancer, melanoma, colorectal cancer and non-small cell lung cancer caused by mutations RAS and/or RAF; and IMM-6-415 to treat solid tumors.
Get a Free Copy of Zacks Immunization Research Report (IMRX)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Immuneering right now?
Before you consider immunization, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Immuneering wasn’t on the list.
Although Immuneering currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here